6 completed, 1 active not recruiting, 1 recruiting, 1 terminated. 5 Phase 1, 3 Phase 2, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 4, Withdrawn 1 |
| Phase 2 | 3 | Completed 1, Terminated 1, Withdrawn 1 |
| Phase 3 | 3 | Active not recruiting 1, Completed 1, Recruiting 1 |
Follow apraglutide: new trials by email Literature Review of apraglutide trials Research Report on apraglutide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Investigate the Efficacy and Safety of Apraglutide Compared With Placebo in Adult Participants With Short Bowel Syndrome Associated With Intestinal Failure (SBS-IF) Apraglutide, Placebo - Short Bowel Syndrome (SBS), SBS Associated With Intestinal Failure (SBS-IF) | Phase 3 | Recruiting | VectivBio AG | 124 | 2026-08-01 | 2026-08-04 |
| Relative Bioavailability of a New Presentation of Apraglutide Versus the Reference Formulation Apraglutide - Healthy Subjects | Phase 1 | Completed | VectivBio AG | 34 | 2023-05-23 | 2024-10-26 |
| Evaluation of Apraglutide on Gastric Emptying Apraglutide, Placebo, Acetaminophen - Healthy Subjects | Phase 1 | Completed | VectivBio AG | 42 | 2023-03-02 | 2024-10-24 |
| A Phase 1 Open-Label Evaluation of the Pharmacokinetics and Safety of a Single Dose of Apraglutide in Subjects With Normal and Impaired Hepatic Function Apraglutide - Hepatic Impairment | Phase 1 | Completed | VectivBio AG | 16 | 2023-01-30 | 2025-07-10 |
| Proof-of-concept Trial of Apraglutide in Acute Graft Versus Host Disease (aGVHD) Apraglutide - GVHD | Phase 2 | Terminated | VectivBio AG | 31 | 2022-05-25 | 2025-10-20 |
| Open-label Extension Trial to Evaluate the Long-term Safety of Apraglutide in Short Bowel Syndrome. Apraglutide - Short Bowel Syndrome | Phase 3 | Active not recruiting | VectivBio AG | 158 | 2021-07-13 | 2025-07-02 |
| Metabolic Balance Study of Apraglutide in Patients With Short Bowel Syndrome, Intestinal Failure (SBS-IF) and Colon-in-Continuity (CIC) Apraglutide - Short Bowel Syndrome | Phase 2 | Completed | VectivBio AG | 10 | 2021-06-14 | 2025-06-18 |
| Trial to Evaluate Efficacy and Safety of Apraglutide in SBS-IF apraglutide - Short Bowel Syndrome | Phase 3 | Completed | VectivBio AG | 164 | 2021-01-26 | 2024-11-27 |
| Study of Pharmacokinetics and Safety of Apraglutide in Participants With Normal and Impaired Kidney Function. Apraglutide - Chronic Kidney Disease | Phase 1 | Completed | VectivBio AG | 16 | 2020-12-08 | 2024-10-26 |
| Safety, Tolerability, PK/PD of FE 203799 in Adults With Lymphomas FE 203799 - Lymphoma, Non-Hodgkin's, Adult, Lymphoma, Hodgkin's, Adult | Phase 1 / Phase 2 | Withdrawn | GlyPharma Therapeutics | 2018-09-01 | 2024-10-24 |
Intestinal Failure (4) · Short Bowel Syndrome (4) · Graft vs Host Disease (1) · Hodgkin Disease (1) · Lymphoma (1) · Mucositis (1) · Renal Insufficiency (1) · Renal Insufficiency, Chronic (1)
VectivBio AG (9) · GlyPharma Therapeutics (1)
Germany (5) · United States (5) · Belgium (4) · France (4) · Spain (4) · Argentina (3) · Czechia (3) · Denmark (3) · Hungary (3) · Israel (3) · Italy (3) · Japan (3) · Netherlands (3) · Poland (3) · South Korea (3)
Tomasz Masior (9)